Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO and managing director Leslie Chong chats with Proactive's Jonathan Jackson live from the ASX Small and Mid Cap Conference in March 2024. The biotech stock is a clinical-stage immuno-oncology company that's developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Chong says the company's pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard-of-care drugs and emerging immunotherapies.
Imugene with Proactive at ASX Small and Mid Cap Conference
